Printer Friendly

DEPRENYL ANIMAL HEALTH, INC. REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL FOR TREATING COGNITIVE DYSFUNCTION (DEMENTIA) IN PET DOGS

 OVERLAND PARK, Kan., Jan. 14 /PRNewswire/ -- Deprenyl Animal Health, Inc. (NASDAQ: DAHI; Toronto Stock Exchange: DAH) reported today it has achieved positive interim results in a continuing clinical trial of Anipryl(R) for the treatment of cognitive dysfunction (dementia) in pet dogs. The company announced in July 1992 that it had received a U.S. patent covering the use of Anipryl (I-deprenyl) to treat this affliction of dogs.
 According to David R. Stevens, president and CEO, "These initial one month clinical trial results on the first 18 pet dogs are quite encouraging. Many of the aging pet dogs enrolled in this program have demonstrated significant clinical improvement during this ongoing pilot trial, in which dosage and methodological issues are being evaluated for the first time. Approximately 60 dogs are currently participating in this clinical trial, and additional refinement and verification will be required in subsequent trials, which we will pursue in the coming months."
 Currently, there are no FDA-approved drugs for the treatment of canine cognitive dysfunction or dementia, a syndrome frequently encountered in pet dogs which is recognized by many veterinarians and pet owners. Normal cognition pertains to thought or to the perception of objects; it includes all aspects of thinking and remembering. Deterioration of normal cognition ( cognitive dysfunction') in clinically afflicted animals is encountered as failing, for example, to recognize or properly respond to familiar persons, places or commands, which may result in euthanasia of the pet.
 "We are pleased to report these results," Dr. Stevens added, "which move us closer to U.S. FDA and Canadian regulatory approval for the use of Anipryl in pet dogs. We believe that Anipryl will provide a significant new option for the therapy of this syndrome in pet dogs."
 As previously reported during 1992, the company has received two other patent allowances from the United States Patent and Trademark Office.
 "The issuance of these three patents" Dr. Stevens noted, "is both a validation of the drug's potential attributes and commercial protection, and a major step forward in the company's comprehensive program to develop Anipryl as a pharmaceutical to enhance the health of pets."
 DAHI was established in 1990 to develop for the United States and Canadian markets animal health applications for the pharmaceutical I-deprenyl. The company is seeking regulatory approval in the United States and Canada for veterinary prescriptive applications of Anipryl (I-deprenyl), first in dogs. The company is also identifying additional animal health product opportunities to become a multi-product animal health pharmaceutical company.
 -0- 1/14/93
 /CONTACT: David R. Stevens, president of Deprenyl Animal Health, Inc., 913-338-2120, or fax, 913-338-3804, or Irving L. Straus of Straus Corporate Communications, 212-768-2477, for Deprenyl Animal Health, Inc./
 (DAHI)


CO: Deprenyl Animal Health, Inc. ST: Kansas IN: MTC SU: ERN

PS-OS -- NY031 -- 4852 01/14/93 11:53 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1993
Words:466
Previous Article:MICROPROSE IS SOFTWARE LICENSEE FOR 3DO INTERACTIVE MULTIPLAYER
Next Article:ARMSTRONG WORLD INDUSTRIES ANNOUNCES SEVERAL SIGNIFICANT DEVELOPMENTS IN CONNECTION WITH ITS 1992 FINANCIAL RESULTS
Topics:


Related Articles
DEPRENYL ANIMAL HEALTH REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL (L-DEPRENYL) FOR CUSHING'S DISEASE IN DOGS
DEPRENYL ANIMAL HEALTH GRANTED PATENT FOR L-DEPRENYL (ANIPRYL) AS TREATMENT OF COGNITIVE DYSFUNCTION IN DOGS
DEPRENYL ANIMAL HEALTH, INC. REPORTS U.S. PATENT ALLOWANCE FOR USE OF ANIPRYL IN TREATMENT OF CANINE CUSHING'S DISEASE
DEPRENYL ANIMAL HEALTH, INC. REPORTS RESULTS OF OPERATIONS FOR THREE MONTHS ENDED SEPT. 30, 1992
DEPRENYL ANIMAL HEALTH, INC. REPORTS ON PHOENIX SCIENTIFIC, INC.
DEPRENYL ANIMAL HEALTH INC. SECURES ADDITIONAL FUNDING FROM DEPRENYL RESEARCH; DRL COMMITS $2.5 MILLION TO FUND DAHI OPERATIONS THROUGH 1995
DEPRENYL ANIMAL HEALTH INC. REPORTS RESULTS OF OPERATIONS FOR THREE AND SIX MONTHS ENDED JUNE 30, 1994
DEPRENYL ANIMAL HEALTH INC. ACHIEVES FIRST EUROPEAN PATENT AND FIFTH U.S. PATENT FOR ANIPRYL(R) THERAPY
DEPRENYL ANIMAL HEALTH, INC. FILES PHASE III EQUIVALENT CLINICAL TRIAL REPORT WITH THE U.S. FDA
Aniprylr Available in Additional Dosages in Canada Shareholders to Vote on DRAXIS Exchange Offer for DAHI Shares

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters